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Background. The ABC-stroke and ABC-bleeding are biomarker-based scores proposed to predict stroke and bleeding, but non-specificity of biomarkers is common, predicting different clinical events at the same time. We assessed the predictive performance of the ABC-stroke and ABC-bleeding scores, for outcomes beyond ischaemic stroke and major bleeding, in a cohort of atrial fibrillation (AF) patients. 
Methods. We included AF patients stable on vitamin K antagonists for 6 months. The ABC-stroke and ABC-bleeding were calculated and the predictive values for myocardial infarction (MI), acute heart failure (HF), a composite of cardiovascular events, and all-cause deaths were compared.
Results. We included 1044 patients (49.2% male; median age 76 [71-81] years). During 6.5 (4.3-7.9) years, there were 58 (5.6%) MIs, 98 (9.4%) acute HFs, 167 (16%) cardiovascular events, and 418 (40%) all-cause deaths. There were no differences in mean ABC-stroke and ABC-bleeding scores in patients with/without MI (p=0.367 and p=0.286, respectively); both scores were higher in patients with acute HF, cardiovascular events or death (all p<0.05). Predictive performances for the ABC-stroke and ABC-bleeding scores were similar, ranging from ‘poor’ for MI (c-indexes ~0.54), ‘moderate’ for acute HF and cardiovascular events (c-indexes ~0.60 and ~0.64, respectively), and ‘good’ for all-cause mortality (c-indexes >0.70). Clinical usefulness whether assessed by ABC-stroke or ABC-bleeding was similar for various primary endpoints.
Conclusions. In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths.  This is consistent with non-specificity of biomarkers that predict ‘sick’ patients or poor prognosis overall.





	Atrial fibrillation (AF) patients often suffer from cardiovascular events, including heart failure (HF) and myocardial infarction (MI).
	In AF patients, the ABC-stroke and ABC-bleeding are biomarker-based scores proposed to specifically predict stroke and bleeding, respectively.
	A common disadvantage of biomarkers is that they are non-specific and could be predictors of different clinical events at the same time.

What does this paper adds?
	In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths.  
	The clinical usefulness and net benefit for the overall risk of various primary endpoints was also similar with the ABC-stroke or ABC-bleeding.






Atrial Fibrillation (AF) is the commonest cardiac arrhythmia worldwide and is associated with increased mortality and morbidity from stroke, thromboembolism and dementia  ADDIN EN.CITE (1). Thus, most clinical guidelines recommend long-term therapy with oral anticoagulants (OACs) to reduce these thromboembolic risks  ADDIN EN.CITE (2-4). Nonetheless, AF patients also commonly suffer from other cardiovascular events, including heart failure (HF) and myocardial infarction (MI)  ADDIN EN.CITE (5, 6).
Several risk prediction rules have been described for AF, mainly focused on stroke and bleeding risk prediction  ADDIN EN.CITE (7, 8). All clinical risk prediction rules only have modest predictive value for identifying the high risk patients that sustain events, thus biomarkers have been added to some clinical risk factors in order to improve their predictive ability for outcomes, and such biomarkers or biomarker-based risk scores have been recommended in guidelines (7). 
In AF patients, the ABC-stroke (Age, Biomarkers and Clinical history) and ABC-bleeding are biomarker-based scores proposed to specifically predict stroke and bleeding, respectively  ADDIN EN.CITE (9, 10). Both ABC scores were derived from randomized clinical trial cohorts of highly selected anticoagulated patients with AF  ADDIN EN.CITE (9, 10) and there is some debate over their the practical ‘real world’ usefulness of biomarkers given that are measured once at baseline with the aim to predict events some time later, often many years  ADDIN EN.CITE (11, 12). Also, there are some difficulties for searching appropriate cut-off values for some biomarkers  ADDIN EN.CITE (13, 14). Most importantly, a common disadvantage of biomarkers is that they are non-specific and could be predictors of different clinical events at the same time (15). 





In our anticoagulation clinic in a tertiary hospital in Murcia (Southeastern Spain), we included consecutive non-valvular AF patients who were stable on VKA therapy for 6-months (i.e. consistently maintaining INRs between 2.0 and 3.0), from May 2007 to December 2007. We excluded patients with rheumatic mitral valves or prosthetic heart valve, and acute coronary syndrome, stroke, unstable chest pain, hemodynamic instability, hospital admissions or surgical interventions in the preceding 6 months. This, alongside with stable VKA therapy, ensures baseline homogeneity avoiding the bias produced by a low TTR or by extremes biomarkers values caused by an acute condition.
Clinical and demographic data were collected at inclusion. Stroke risk was calculated using the CHA2DS2-VASc score and the bleeding risk was estimated using the HAS-BLED score. Additionally, the ABC-stroke and ABC-bleeding scores were calculated using an Excel-based calculator that performed the results according to the modified nomograms proposed by Hijazi et al.  ADDIN EN.CITE (9, 10). We used the “troponin T” and “creatinine clearance” versions of the nomograms for the ABC-stroke and ABC-bleeding scores, respectively. 

Blood Samples and Laboratory Analysis
At baseline, blood samples were drawn at baseline atraumatically and without stasis into blood collection tubes containing 3.8% (0.129 M) trisodium citrate. Samples were centrifuged at 2,200 g and 4°C for 10 min, and the supernatants were stored in aliquots at -80°C until further use. High sensitivity troponin T (hsTnT) and N-terminal fragment B-type natriuretic peptide (NT-proBNP) levels were assessed by electrochemiluminescence using an automated analyser (Cobas e 601, Roche Diagnostica, Mannheim, Germany). The intra-assay coefficient of variation was 5.6% and the lower limits of detection of these assays were 3.0 pg/mL for hsTnT and 5.0 pg/mL for NT-proBNP.
The estimated glomerular filtrate rate (eGFR) was calculated by using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.

Clinical outcomes and follow-up
The primary endpoints for this study were MI (defined according to the 4th Universal Definition of MI  ADDIN EN.CITE (13), acute HF, a composite of cardiovascular events (any of the following: MI, HF or cardiac-related death), and all-cause death. Acute HF was defined as a gradual or rapid change in the signs and symptoms of HF, resulting in a need for urgent therapy, whereas cardiac-related death was defined as sudden death, death caused by progressive congestive HF or fatal MI, or procedure-related death.
During follow-up, the investigators identified, confirmed, and recorded all adverse events. Follow-up was performed by personal interview at each visit to the anticoagulation clinic and through medical records. No patient was lost to follow-up. 
The study was performed according the ethical principles of Declaration of Helsinki and Good Clinical Practice Guidelines, was approved by the Ethical Committee from University Hospital Morales Meseguer (Murcia, Spain), and all patients signed an informed consent to participation.

Statistical analysis
Continuous variables were tested for normality according to the Kolmogorov-Smirnov test and quantitative variables are presented as mean±SD (standard deviation) or median (interquartile range, IQR). Categorical variables were expressed as absolute frequencies and percentages. The Student's T or the Mann-Whitney U tests were used to compare continuous and categorical variables, as appropriate. 
Receiver-operating characteristic curves (ROC) were calculated to evaluate the predictive ability (expressed as c-indexes) of the ABC-stroke and the ABC-bleeding for the different endpoints. The predictive performances of the scores were compared using the method of DeLong et al (16). An estimation of the net benefit and the clinical usefulness of both scores was performed using decision curve analysis (DCA), as described by Vickers et al (17). DCAs help in the estimation of patients who will suffer any primary endpoint, based on the predictions of one of the risk scores in comparison with the other. In the DCAs, the X-axis shows threshold values for primary endpoints risks while the Y-axis represents the net benefit for the different threshold values of primary endpoints risk. The farther are the prediction models from the dashed black line and the horizontal black line, the higher net benefit.






We included 1044 patients (49.2% male) with a median age of 76 years (IQR 71-81). Median CHA2DS2-VASc and HAS-BLED scores were 4 (IQR 3-5) and 2 (IQR 2-3), respectively; whereas the median ABC-stroke was 9.2 (IQR 7.3-11.3) and the median ABC-bleeding was 16.5 (IQR 14.3-18.6). An overview of baseline clinical characteristics is showed in Table 1.
During a follow-up of 6.5 (IQR 4.2-7.9) years, there were 58 MI events (5.6%, 0.85 per 100 patient-year), 98 with acute HF (9.4%, 1.44 per 100 patient-year), 167 with composite cardiovascular events (i.e. any of MI, HF or cardiac-related death: 16%, 2.46 per 100 patient-year), and 418 all-cause deaths (40%, 6.71 per 100 patient-year). 
There were no significant differences in the ABC-stroke and ABC-bleeding scores in AF patients with or without MI during the follow-up (p=0.367 and 0.286, respectively); both scores were significantly higher in those patients who suffered acute HF, composite cardiovascular events or death (all p<0.05).
Similar results were found for the individual biomarkers and laboratory parameters included in the ABC-stroke and the ABC-bleeding scores, whereby none were significantly increased at baseline in patients who suffered MI. Only hsTnT was higher in patients developing acute HF, whereas hsTnT, NT-proBNP and hemoglobin were higher in patients with a composite cardiovascular event (Table 2). All biomarkers, including creatinine-clearance, were significantly higher in patients who died (Table 2).

Predictive performances  
Both ABC-stroke and the ABC-bleeding scores demonstrated a poor ability in predicting MI (c-indexes ~0.54), moderate ability in predicting acute HF and composite cardiovascular events (c-indexes ~0.60 and ~0.64, respectively), and good ability in predicting all-cause mortality (c-indexes >0.70) (Table 3). 





The ABC-stroke and ABC-bleeding are biomarker-based scores were proposed as improvements over conventional clinical risk scores to specifically predict stroke and bleeding, respectively. In this ‘real world’ study of anticoagulated patients with AF, our principal finding was that both ABC-stroke and ABC-bleeding scores showed similar predictive ability for various adverse events, ranging from ‘poor’ for MI, ‘moderate’ for acute HF and composite cardiovascular events, and ‘good’ for all-cause mortality. 
	The ABC-stroke and ABC-bleeding scores were derived and validated in anticoagulated patient cohorts from randomized clinical trials  ADDIN EN.CITE (9, 10). Both are biomarker-based scores which provide incremental information about stroke and bleeding risks over clinical risk factors alone. Ever since the first demonstration of using biomarkers in AF to improve clinical risk stratification >10 years ago, there has been the quest for new and novel AF-related biomarkers (18). Nevertheless, biomarkers are often not specific of a particular disease, but increased in many diverse disease states, both cardiovascular and non-cardiovascular (7). 
	For example, serum cardiac troponin T (cTnT) begins to rise within three to four hours after the onset of myocardial injury, remains increased for 10-14 days, and is a sensitive indicator of MI, damage and raised risk of re-infarction and mortality in patients with acute coronary syndrome (19). cTnT is also associated with progressive left ventricular (LV) dysfunction in patients with HF  ADDIN EN.CITE (20), as also shown in the present study. Nevertheless, cTnT elevation is common in many other diseases, such as stroke, sepsis, hypovolemia, Tako-Tsubo cardiomyopathy, pulmonary embolism, sepsis, acute aortic dissection, acute perimyocarditis and myocardial contusion  ADDIN EN.CITE (21, 22). In elderly healthy men, troponin levels predicted coronary heart disease events and mortality independent of conventional major coronary risk factors (23). 
Another example is B-Type natriuretic peptide (BNP), which has been described as a marker of LV function, and as effective tool for detecting HF or LV systolic and diastolic dysfunction (24). BNP also has a significant role into the prognosis of target organ damage in patients with hypertension or acute pulmonary embolism  ADDIN EN.CITE (25). The effects of NT-proBNP on diuresis and natriuresis in congestive HF represent a compensatory mechanism for stress in myocytes, leading to ventricular dysfunction (26). In addition, NT-proBNP is correlated with the symptoms and echocardiographic severity of mitral stenosis and unstable angina (27), and is a biomarker of the damage caused by cardiac ischemia or acute coronary syndrome, with prognostic implications (26).
The biomarkers incorporated into the ABC-bleeding score are hemoglobin (Hb), hsTnT and creatinine clearance. Previous studies have suggested that an abnormal concentration of Hb is a consequence of preclinical cardio- or cerebro- vascular disease and not a predisposing factor  ADDIN EN.CITE (28). There are also numerous causes of anaemia, including chronic disease states, bone marrow depression from increased levels of proinflammatory cytokines  ADDIN EN.CITE (29, 30), iron or vitamin-deficiency (31), malnutrition, kidney dysfunction  ADDIN EN.CITE (32, 33), impaired erythropoietin production or resistance, hemoglobinopathies and some angiotensin-converting enzyme (ACE) inhibitors  ADDIN EN.CITE (34-36). All-cause mortality and stroke are increased when the Hb concentration was lower than 12 g/dL and higher than 14 g/dL  ADDIN EN.CITE (37). When anaemia is chronic, reduced perfusion leads to increasing the preload and decreasing the afterload, thus inducing LV hypertrophy  ADDIN EN.CITE (38). In addition, low hematocrit produces changes in the metabolism of nitric oxide, activating erythrocyte-derived adenosine diphosphate (39), which stimulates platelet adhesion, thus raising the risk of atherosclerosis and thrombosis causing ischemic vascular disease (40). Finally, the Creatinine Clearance (CrCl) is the result of the amount of creatinine that has been cleaned from the blood by the kidneys in a 24-hour time period, and low CrCl may suggest kidney disease or other diverse conditions affecting kidney function  ADDIN EN.CITE (41-45) or urinary tract obstruction (46).
	In the present study, the ABC-stroke score showed a similar predictive ability for MI, HF and cardiovascular events compared that previously reported for stroke in the same AF cohort  ADDIN EN.CITE (47). Of note, the ABC-bleeding score showed even better predictive ability for MI, HF and cardiovascular events, than for the bleeding events  ADDIN EN.CITE (48). Of note, the highest (and similar) predictive performance found in this study for both ABC scores was for mortality. Our observations suggest that biomarkers would improve risk prediction of ‘high risk’ AF patients for adverse outcomes, at least statistically. Nonetheless, their practical role to specifically aid stroke and bleeding risk stratification in everyday practice may be limited, given that they are more likely reflective of a sick patient or a sick heart. 
Simple and dynamic risk assessment using validated risk scores in daily clinical practice should focus on modifiable ischemic and bleeding risk factors at every patient contact, and therefore the appropriate use of risk scores should be to “flag up” high-risk patients for more careful review and follow-up(49). As well as being non-specific, many biomarkers are also open to diurnal variation and assay variability, and (as shown in the present study) are equally predictive of multiple endpoints including stroke, bleeding, death, HF, hospitalizations, etc. Indeed, one biomarker proposed as a specific bleeding predictor, GDF-15 also predicts glaucoma progression (50).
Importantly, some biomarkers for risk prediction are based on data from highly selected clinical trial cohorts, which have not studied the broad range of patients seen in everyday practice. Many studies have also measured biomarker levels near baseline (eg. 0-6 months) and have related levels to remote outcomes many years later, not accounting for ageing, incident risk factors and changes in drug therapies  ADDIN EN.CITE (51-53). Indeed, risk stratification in AF patients is not a “one off” process, as patient’s risk is dynamic and does not remain static. The use of biomarkers also increases costs, loses simplicity and practicality.
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Table 1. Baseline clinical characteristics.
	N = 1044
Demographic	
Male sex, n (%)	514 (49.2)






History of stroke/TIA/thromboembolism	204 (19.5)
Renal impairment	110 (10.5)
Coronary artery disease	210 (20.1)
Hypercholesterolemia	349 (33.4)
Current smoking habit	167 (16.0)
Current alcohol consumption	35 (3.4)
History of previous bleeding	86 (8.2)
Concomitant malignant disease	80 (7.7)
	











CHA2DS2-VASc, median (IQR)	4 (3-5)
HAS-BLED, median (IQR)	2 (2-3)







Table 2. Biomarkers levels and risk scores in patients with and without primary endpoints.
	Myocardial infarction	Acute heart failure	Composite cardiovascular events	All-cause mortality
















Table 3. Comparison of the ABC-stroke and ABC-bleeding predictive abilities for the different primary endpoints.
	ABC-stroke	ABC-bleeding	p-value*
	C-index (95% CI)	C-index (95% CI)	
Myocardial infarction	0.535 (0.504-0.566)	0.542 (0.511-0.572)	0.880
Acute heart failure	0.600 (0.564-0.624)	0.614 (0.584-0.644)	0.504
Composite cardiovascular events 	0.644 (0.615-0.674)	0.644 (0.613-0.672)	0.946
All-cause mortality	0.704 (0.676-0.732)	0.726 (0.698-0.753)	0.187






Figure 1. Decision curve analyses for the primary endpoints.




